The Effect of RFC G80A Polymorphism in Cretan children with acute lymphoblastic leukemia and its interaction with MTHFR C677T and A1298C polymorphisms

International Journal of Laboratory Hematology

Volumn 36, Issue 4, 2014, Pages 425-430

  Karathanasis, N V ^a   Stiakaki, E ^a   Goulielmos, G N ^b   Kalmanti, M ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

ALL; MTHFR; PCR; RFC; RFLP; SNPs

Indexed keywords

HEMOGLOBIN; METHOTREXATE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; REDUCED FOLATE CARRIER; ANTINEOPLASTIC ANTIMETABOLITE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN; SLC19A1 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLOOD TOXICITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOCYTE COUNT; ALLELE; CASE CONTROL STUDY; EPISTASIS; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GREECE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD;

ALLELES; ANTIMETABOLITES, ANTINEOPLASTIC; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; EPISTASIS, GENETIC; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GREECE; HUMANS; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REDUCED FOLATE CARRIER PROTEIN;

EID: 84904406095     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/ijlh.12160     Document Type: Article

References (20)

1. Pui CH, Evans WE. Drug therapy-treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-78.
2. Wiemels JL, Smith RN, Taylor GM, et al. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukaemia. Proc Natl Acad Sci USA 2001;98:4004-9.
3. Karathanasis NV, Choumerianou DM, Kalmanti M. Gene polymorphisms in childhood ALL. Pediatr Blood Cancer 2009;52:318-23.
4. Chango A, Emery-Fillon N, Potier de Courcy G, et al. A Polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 2000;70:310-15.
5. Laverdiere C, Chiasson S, Costea I, et al. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002;100:3832-4.
6. Zanrosso CW, Hatagima A, Emerenciano M, et al. The role of methylenetetrahydrofolate reductase in acute lymphoblastic leukemia in a Brazilian mixed population. Leuk Res 2006;30:477-81.
7. Weisberg I, Tran P, Christensen B, et al. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998;64:169-72.
8. Taub JW, Matherly LH, Ravindranath Y, et al. Polymorphisms in methylenetetrahydrofolate reductase and methotrexate sensitivity in childhood acute lymphoblastic leukemia. Leukemia 2002;16:764-5.
9. Krajinovic M, Lemieux-Blanchard E, Chiasson S, et al. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J 2004;4:66-72.
10. Karathanasis NV, Stiakaki E, Goulielmos GN, Kalmanti M. The role of the methylenetetrahydrofolate reductase 677 and 1298 polymorphisms in Cretan children with acute lymphoblastic leukemia. Genet Test Mol Biomarkers 2011;15:5-10.
11. Common Terminology Criteria for Adverse Events v4.0 (CTCAE). U.S. Department Of Health And Human Services. National Institutes of Health. National Cancer Institute.
12. De Jonge R, Tissing WJE, Hooijberg JH. Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia. Blood 2009;113:2284-9.
13. Shimasaki N, Mori T, Samejima H, et al. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2006;28:64-8.
14. Imanishi H, Okamura N, Yagi M, et al. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet 2007;52:166-71.
15. Ashton LJ, Gifford AJ, Kwan E, et al. Reduced folate carrier and methylenetetrahydrofolate reductase gene polymorphisms: associations with clinical outcome in childhood acute lymphoblastic leukemia. Leukemia 2009;23:1348-51.
16. Rocha JCC, Cheng C, Liu W, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 2005;105:4752-8.
17. Oliveira E, Alves S, Quental S, et al. The MTHFR C677T and A1298C polymorphisms and susceptibility to childhood acute lymphoblastic leukemia in Portugal. J Pediatr Hematol Oncol 2005;27:425-9.
18. Schnakenberg E, Mehles A, Cario G, et al. Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population. BMC Med Genet 2005;6:23.
19. Petra BG, Janez J, Vita D. Gene-gene interactions in the folate metabolic pathway influence the risk for acute lymphoblastic leukemia in children. Leuk Lymphoma 2007;48:786-92.
20. Krajinovic M, Lamothe S, Labuda D, et al. Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukaemia. Blood 2004;103:252-7.